Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme, FDA Warn Of Foreign Particles Found In Some Lots Of Five Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Although the drugs in question all are manufactured or finished and filled at the Allston Landing, Mass., plant, Genzyme says the current difficulty is not related to prior manufacturing problems associated with that facility.

You may also be interested in...



FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification

A Form 483 posted online by FDA following a five-week inspection of the Allston Landing manufacturing plant cites 49 separate concerns.

FDA Inspection Of Genzyme Plant Finds Lack Of Follow-up, Old Equipment, Poor Personnel Qualification

A Form 483 posted online by FDA following a five-week inspection of the Allston Landing manufacturing plant cites 49 separate concerns.

Shire Seizes On Gaucher Opening With EMEA Filing For Velaglucerase

Given the shortage of Genzyme's Cerezyme treatment, European regulators decided to grant an accelerated review for Shire's medication.

Related Content

Topics

UsernamePublicRestriction

Register

PS068748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel